We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I wonder why this article wasn't posted on the Burnet website until 25 September.
Possibly to highlight the fact that they are now using the same CD4 technology to develop a rapid hand held point of care COVID test.
“The technology and philosophy behind the CD4 test, he said, was being applied to other Burnet point-of-care tests currently in development for other diseases, including COVID-19 and sepsis”
It’s worth reading the whole article and watching the 1 minute video clip at the end.
Link from Burnet website again:
https://burnet.edu.au/news/1299_who_endorses_burnet_hiv_diagnostic
So that’s surely more good news for ODX!
And as said before we should get details of Omega’s “ significant orders and interest from African, Latin American and Asian countries” imminently if that is indeed the case!
Fingers crossed it is orders news. Maybe it's news from Nigeria? Hopefully its not eluding to capacity guarantee already discussed with care agencies. $4 a test on a 70% margin sounds good to me. Colin did say the were expecting orders this financial year regarding CD4.
“Lots of orders” wasn’t in the August RNS.
Orders deserves RNS’d
This was in the RNS on the 21st August 2020.
Fanastic endorsement of the cd4 test by the WHO, big news for the company, they have worked hard for this.
thanks for taking a lead carados. ...pulling together well informed articles is so important.... sincerely Fred
The deals are being made and so begin the company profits. Sit back and watch the share price rise independently of Covid.
Then of course, there’s Covid.
Thanks Show. Only passing the info I find on twitter so people here can see. Thanks should go to the real investigators out there.
Great news Carados, thanks.....this part especially:
“He said working with good partners, including Omega Diagnostics, which has commercialised and manufactured the VISITECT® CD4 Advanced Disease Test, as well as strong collaborations with Rush University and Duke University in the USA, showed Burnet’s diagnostics team could make a lasting impact on global health.
Omega Diagnostics has attracted significant orders and interest from African, Latin American and Asian countries for the test”
And thanks for the twitter link for RTC
https://burnet.edu.au/news/1299_who_endorses_burnet_hiv_diagnostic